EVOK Quote, Financials, Valuation and Earnings

MEI Pharma has a net margin of -49.45% compared to Evoke Pharma's net margin of --. Evoke Pharma's return on equity of -433.12% beat MEI Pharma's return on equity of --.

Evoke Pharma has a consensus price target of --, signalling upside risk potential of 253.64%. On the other hand MEI Pharma has an analysts' consensus of -- which suggests that it could grow by 700%. Given that MEI Pharma has higher upside potential than Evoke Pharma, analysts believe MEI Pharma is more attractive than Evoke Pharma.

Evoke Pharma has a beta of 0.162, which suggesting that the stock is 83.83% less volatile than S&P 500. In comparison MEI Pharma has a beta of 0.790, suggesting its less volatile than the S&P 500 by 21.017%.

Evoke Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MEI Pharma offers a yield of 0% to investors and pays a quarterly dividend of $1.75 per share. Evoke Pharma pays -- of its earnings as a dividend. MEI Pharma pays out 65.59% of its earnings as a dividend. MEI Pharma's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Evoke Pharma quarterly revenues are $2.7M, which are larger than MEI Pharma quarterly revenues of --. Evoke Pharma's net income of -$1.3M is higher than MEI Pharma's net income of -$8M. Notably, Evoke Pharma's price-to-earnings ratio is -- while MEI Pharma's PE ratio is 1.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma is 0.56x versus 0.16x for MEI Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -49.45% compared to Evoke Pharma's net margin of -49.65%. Evoke Pharma's return on equity of -433.12% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Evoke Pharma has a consensus price target of --, signalling upside risk potential of 253.64%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Evoke Pharma, analysts believe NovaBay Pharmaceuticals is more attractive than Evoke Pharma.

Evoke Pharma has a beta of 0.162, which suggesting that the stock is 83.83% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.

Evoke Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Evoke Pharma quarterly revenues are $2.7M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Evoke Pharma's net income of -$1.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Evoke Pharma's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma is 0.56x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -49.45% compared to Evoke Pharma's net margin of -2357.27%. Evoke Pharma's return on equity of -433.12% beat Palatin Technologies's return on equity of --.

Evoke Pharma has a consensus price target of --, signalling upside risk potential of 253.64%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Evoke Pharma, analysts believe Palatin Technologies is more attractive than Evoke Pharma.

Evoke Pharma has a beta of 0.162, which suggesting that the stock is 83.83% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.

Evoke Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Evoke Pharma quarterly revenues are $2.7M, which are larger than Palatin Technologies quarterly revenues of $350K. Evoke Pharma's net income of -$1.3M is higher than Palatin Technologies's net income of -$7.8M. Notably, Evoke Pharma's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma is 0.56x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Revance Therapeutics has a net margin of -49.45% compared to Evoke Pharma's net margin of -63.65%. Evoke Pharma's return on equity of -433.12% beat Revance Therapeutics's return on equity of --.

Evoke Pharma has a consensus price target of --, signalling upside risk potential of 253.64%. On the other hand Revance Therapeutics has an analysts' consensus of $7.64 which suggests that it could grow by 147.96%. Given that Evoke Pharma has higher upside potential than Revance Therapeutics, analysts believe Evoke Pharma is more attractive than Revance Therapeutics.

Evoke Pharma has a beta of 0.162, which suggesting that the stock is 83.83% less volatile than S&P 500. In comparison Revance Therapeutics has a beta of 0.815, suggesting its less volatile than the S&P 500 by 18.478%.

Evoke Pharma has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revance Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evoke Pharma pays -- of its earnings as a dividend. Revance Therapeutics pays out -- of its earnings as a dividend.

Evoke Pharma quarterly revenues are $2.7M, which are smaller than Revance Therapeutics quarterly revenues of $59.9M. Evoke Pharma's net income of -$1.3M is higher than Revance Therapeutics's net income of -$38.1M. Notably, Evoke Pharma's price-to-earnings ratio is -- while Revance Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evoke Pharma is 0.56x versus 1.16x for Revance Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.